2 Information about foslevodopa–foscarbidopa

Marketing authorisation indication


Foslevodopa–foscarbidopa (Produodopa, AbbVie) is indicated for the 'treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results'.

Dosage in the marketing authorisation



The cost of foslevodopa–foscarbidopa is £84.70 for a 10‑ml vial for infusion (excluding VAT; company submission).


The company has a commercial arrangement. This makes foslevodopa–foscarbidopa available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)